Kurihara M, Ogawa M, Ohta T, Kurokawa E, Kitahara T, Murata A, Matsuda K, Kosaki G, Watanabe T, Wada H
Cancer Res. 1984 May;44(5):2240-3.
A method for radioimmunoassay of human pancreatic RNase was developed. The method is sensitive, reproducible, and specific. Almost no cross-reactivity exists between human pancreatic and liver RNases. A good correlation was observed between the serum concentration of pancreatic RNase as measured by radioimmunoassay and its enzymatic activity using polycytidylic acid as substrate. The concentration of serum pancreatic RNase correlates well with age, blood urea nitrogen, and albumin contents but does not correlate with serum amylase activity. Using the data of 52 patients with malignant tumors except pancreatic cancer, serum RNase level could be expressed by a multiple regression equation: Immunoreactive RNase content in pancreatic cancer was elevated in patients with complications from renal failure. Serum pancreatic RNase contents in patients with pancreatic cancer measured by radioimmunoassay agreed well with the values calculated using the equation derived from the data of patients with other malignant tumors.
建立了一种人胰腺核糖核酸酶的放射免疫测定方法。该方法灵敏、可重复且特异。人胰腺核糖核酸酶与肝脏核糖核酸酶之间几乎不存在交叉反应。通过放射免疫测定法测得的胰腺核糖核酸酶血清浓度与其以聚胞苷酸为底物的酶活性之间观察到良好的相关性。血清胰腺核糖核酸酶浓度与年龄、血尿素氮和白蛋白含量密切相关，但与血清淀粉酶活性无关。利用52例非胰腺癌恶性肿瘤患者的数据，血清核糖核酸酶水平可用多元回归方程表示：肾衰竭并发症患者胰腺癌中的免疫反应性核糖核酸酶含量升高。通过放射免疫测定法测得的胰腺癌患者血清胰腺核糖核酸酶含量与使用从其他恶性肿瘤患者数据得出的方程计算的值非常吻合。
